Join today and have your say! It’s FREE!

We will not release or resell your information to third parties without your permission.

Please Try Again

{{ error }}

By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Please Try Again

{{ error }}

Password Hint : {{passwordHint}}

Remember me

Forgot Password?

or

Privacy Policy | Disclaimer

Quote | Bullboard | News | Opinion | Profile | Peers | Filings | Financials | Options | Price History | Ratios | Ownership | Insiders | Valuation

Breaking & Recent News Csl ADR CSLLY

Healthcare Biotechnology

CSL Limited is an Australia-based biotechnology company. The Company’s areas of focus include rare and serious diseases, influenza vaccines and iron deficiency and nephrology. The Company’s segments include CSL Behring, CSL Seqirus and CSL Vifor. The CSL Behring segment manufactures, markets and distributes plasma products, gene therapies and recombinants. The CSL Seqirus segment manufactures... see more

Add To Watchlist

Recent & Breaking News (OTCQX:CSLLY)

CSL Behring Announces FDA Approval of Privigen® [Immune Globulin Intravenous (Human), 10% Liquid] for the Treatment of Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) in Adults

PR Newswire September 14, 2017

CSL Behring Joins Together With Conference Attendees to Make Donation to IPOPI

PR Newswire September 14, 2017

CSL Behring to Acquire Biotech Company Calimmune and its Proprietary Stem Cell Gene Therapy Platform

PR Newswire August 28, 2017

HAEGARDA® (C1 Esterase Inhibitor Subcutaneous [Human]) Now Available in the United States for Patients with Hereditary Angioedema

PR Newswire July 25, 2017

CSL Behring Receives Orphan-Drug Exclusivity for HAEGARDA® (C1 Esterase Inhibitor Subcutaneous [Human])

PR Newswire July 21, 2017

FDA Accepts CSL Behring's Supplemental Biologics License Application for Hizentra® Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Indication

PR Newswire July 19, 2017

New Data Demonstrate Prophylactic Treatment with IDELVION® Reduces Bleed Frequency and Has Potential to Positively Impact Patients with Haemophilia B

PR Newswire July 12, 2017

CSL Behring Awards Researchers to Advance Immunoglobulin Therapy in Treating Neurological Disorders

PR Newswire July 11, 2017

New Findings Show AFSTYLA® Provides Long-lasting Efficacy without Increased Product Consumption for Prophylactic and On-Demand Treatment of Haemophilia A

PR Newswire July 10, 2017

New Data for Two Leading Haemophilia Medicines -- AFSTYLA® and IDELVION® -- to be Presented at the International Society on Thrombosis and Haemostasis Congress 2017

PR Newswire July 6, 2017

FDA Approves HAEGARDA® (C1 Esterase Inhibitor Subcutaneous [Human]), First and Only Subcutaneous Preventive Treatment for Hereditary Angioedema

PR Newswire June 23, 2017

CSL to acquire majority stake in Chinese plasma fractionator Wuhan Zhong Yuan Rui De Biologicals Products

PR Newswire June 12, 2017

New Innovation in the Fight Against Hemophilia Earns CSL Behring the NORD 2017 Industry Innovation Award

PR Newswire May 19, 2017

Wirecard North America and CSL Plasma Launch First Cash-Back Donor Prepaid Card

PR Newswire Europe Non Regulatory April 25, 2017

Improving Access to Lifesaving Treatments for Bleeding Disorders in the Developing World

PR Newswire April 10, 2017

Jeffrey Modell Foundation to Open the First North African Network for Primary Immunodeficiencies

PR Newswire March 31, 2017

CSL Behring Awards Grant To Patient Groups To Develop Innovative Ways To Advocate For Patients

PR Newswire March 29, 2017

Jeffrey Modell Foundation to Open the First North African Network for Primary Immunodeficiencies

PR Newswire March 29, 2017

New England Journal of Medicine Publishes Pivotal Phase III Data for CSL Behring's Subcutaneous C1-Esterase Inhibitor in HAE Patients

PR Newswire March 22, 2017

Largest Ever CIDP Clinical Study Completed

PR Newswire March 1, 2017